Importance of combined-modality therapy for primary bone lymphoma.
Primary bone lymphoma (PBL) is a rare entity and comprises about 5% of all extranodal non-Hodgkin's lymphomas (NHL) and 7% of all primary bone tumors. To date there is no consensus about the optimal treatment for PBL. We retrospectively reviewed all cases of PBL treated at Hospital São Paulo, Brazil, over a 10-year-period (January 1992-January 2002). Medical records of 7 patients with PBL were reviewed and information on age at diagnosis, sex, NHL clinical staging (CS), treatment and response to treatment were retrieved. Five patients (72%) received combined-modality therapy (CMT) and all of them are in complete remission (CR) with a median follow up of 19 months (ranging from 12 to 144 months). We conclude that PBL is a potentially curable malignancy and treatment should be undertaken in a multiprofessional approach, in order to provide the best support which probably has to include chemotherapy, radiotherapy and, for patients with IPI higher than 2, consolidation with stem-cell transplantation.
Baiocchi
O C G
OC
Colleoni
G W B
GW
Rodrigues
C A
CA
Barton
D
D
Kerbauy
F R
FR
Garcia
R J
RJ
Segreto
R A
RA
Alves
A C
AC
Bordin
J O
JO
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000150:complications / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000628:therapy*; D008875:Middle Aged; D012074:Remission Induction; D012189:Retrospective Studies